- Previous Close
0.0140 - Open
0.0140 - Bid 0.0135 x --
- Ask 0.0149 x --
- Day's Range
0.0140 - 0.0140 - 52 Week Range
0.0080 - 0.0197 - Volume
63,800 - Avg. Volume
136,489 - Market Cap (intraday)
5.16M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in health care solutions, including ophthalmology, dermatology, transplants, and biomanufacturing. It has a collaboration research agreement with the University of British Columbia. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Dalton, Ohio.
www.protokinetix.comRecent News: PKTX
View MorePerformance Overview: PKTX
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PKTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PKTX
View MoreValuation Measures
Market Cap
5.16M
Enterprise Value
5.16M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
15.08
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-48.09%
Return on Equity (ttm)
-93.63%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-364.19k
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
-4.7k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-148.03k